<DOC>
	<DOCNO>NCT00689078</DOCNO>
	<brief_summary>The purpose study determine whether prednisolone acetate 1 % ophthalmic suspension effective preventing sign symptom allergic conjunctivitis comparison prednisolone acetate 0.12 % ophthalmic suspension , loteprednol etabonate 0.2 % ophthalmic suspension placebo modify conjunctival allergen challenge ( CAC ) model .</brief_summary>
	<brief_title>Evaluation Efficacy Topical Ophthalmic Steroids Modified Conjunctival Allergen Challenge Model</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>At least 18 year age &amp; either sex , race Willing able follow instruction Positive history ocular allergy Reproducible positive ocular allergic reaction induce conjunctival allergen challenge Have plan surgery trial period Female currently pregnant , plan pregnancy lactate Use disallow medication Have ocular infection , ocular condition could affect study parameter Have moderate severe dry eye Have use investigational drug device within 30 day start study Female currently pregnant , plan pregnancy lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Allergic conjunctivitis</keyword>
</DOC>